The Impact of Javanica Oil Emulsion Injection on Chemotherapy Efficacy and Cellular Immune Indicators in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis

Abstract

Background: This meta-analysis aimed to evaluate the efficacy and safety of Javanica oil emulsion injection (JOI) combined with chemotherapy versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC).

Methods: Electronic databases including EMBASE, PUBMED, the Cochrane library, and Chinese Biological Medical disc (CBM) were searched until May 2018. The clinical trials reporting efficacy and immune function of JOI combined with chemotherapy versus chemotherapy in advanced NSCLC were included according to the inclusion and exclusion criteria. Stata 11 and RevMan 5.3 were used for meta-analysis.

Results: Twenty-four studies involving 2089 cases were included. The results of the meta-analysis showed that there were significant differences in objective response rate (risk ratio (RR) = 1.17; 95% confidence interval (CI): 1.05-1.29; P < 0.05), improvement in Karnofsky Performance Status (standard mean difference (SMD) = 1.59; 95% CI: 1.41-1.77; P < 0.01), incidence of adverse events (RR = 0.78; 95% CI: 0.7-0.87; P < 0.05), percentage changes of CD₃ ⁺ cells (SMD = 2.0; 95% CI: 1.49-2.50; P < 0.01), CD₄ ⁺ cells (SMD = 1.55; 95% CI, 1.2-1.9; P < 0.01), natural killer cells (SMD = 1.98; 95% CI: 1.15-2.82; P < 0.01), but not CD₈ ⁺ (SMD = -1.44; 95% CI: -4.53-1.65; P=0.36), and value of CD₄ ⁺/CD₈ ⁺ (SMD = 0.32; 95% CI: 0.28-0.36; P < 0.01) between the JOI combination group and control group. Funnel plot and Begg's and Egger's analysis indicated that there was no significant publication bias (P > 0.05).

Conclusions: JOI may be effective to improve the efficacy of chemotherapy in advanced NSCLC patients, accompanied with better levels of immune cells.